ADVENTRX to Present at CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference
April 02 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, April 2 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that Evan M. Levine, chief executive officer, will
present a corporate overview at the CIBC World Markets Annual
Biotechnology and Specialty Pharmaceuticals Conference on Thursday,
April 12 at 9:10 a.m. Eastern Time. For more information on the
conference, visit http://conferences.cibcwm.com/biotech07/. About
ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. The Company's lead
product candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b
clinical trials for the treatment of metastatic colorectal cancer,
as well as in a Phase 2 clinical trial for the treatment of
advanced breast cancer. More information can be found on the
Company's web site at http://www.adventrx.com/. Forward Looking
Statement ADVENTRX cautions you that statements included in this
press release that are not a description of historical facts are
forward-looking statements that involve risks, uncertainties,
assumptions and other factors that, if they do not materialize or
prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. The potential risks and
uncertainties that could cause actual results to differ materially
include, but are not limited to: uncertainties inherent in the drug
development process; the timing and success of clinical trials; the
validity of research results; the receipt of necessary approvals
from the FDA and other regulatory agencies; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
public filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at http://www.sec.gov/. ADVENTRX does not
intend to update any forward-looking statement, including as set
forth in this press release, to reflect events or circumstances
arising after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Ioana C. Hone of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866; or Amy Martini of WeissComm
Partners, +1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc. Web
site: http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024